Reply to: Technical challenges of studying the impact of plasma components on the efficacy of lipid nanoparticles for vaccine and therapeutic applications

Kai Liu, Elisa Lázaro-Ibáñez, Michael Lerche, Daniel Lindén, Anna Salvati and Alan Sabirsh ()
Additional contact information
Kai Liu: AstraZeneca
Elisa Lázaro-Ibáñez: AstraZeneca
Michael Lerche: AstraZeneca
Daniel Lindén: AstraZeneca
Anna Salvati: University of Groningen
Alan Sabirsh: AstraZeneca

Nature Communications, 2024, vol. 15, issue 1, 1-4

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-47726-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47726-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-47726-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().